Sponsors (2)
The bill promotes awareness, targeted screening, and federal reporting that could improve early detection and inform policy, but it risks higher short-term costs, overdiagnosis, limited immediate access improvements, and potential equity concerns.
People at higher risk (patients with chronic conditions and older adults) may get earlier diagnosis and fewer esophageal cancers because the bill promotes awareness, screening, and outpatient treatment of Barrett’s esophagus.
Federal employees and retirees: a GAO report on FEHBP esophageal cancer spending and screening will identify spending patterns and screening gaps, enabling Congressional oversight and potential policy or coverage changes to control costs and improve care.
Clinicians and health systems (including gastroenterologists and primary care) may adopt more targeted, guideline-aligned endoscopic screening, improving the efficient use of endoscopy for higher-risk patients.
Patients and taxpayers: Expanded screening and more endoscopies could increase overall healthcare spending and raise out-of-pocket costs for patients.
Patients at risk (including older adults): Expanded screening may lead to overdiagnosis and unnecessary procedures, exposing people to procedural risks without clear benefit.
Federal enrollees and patients: The GAO reporting requirement only produces data and does not itself fund screening or change FEHBP coverage, so immediate improvements in access to screening or care are uncertain.
Based on analysis of 3 sections of legislative text.
Requires the GAO to report within one year on FEHBP esophageal cancer spending and whether high‑risk FEHBP enrollees receive guideline‑recommended screening.
Directs the Government Accountability Office (GAO) to study how much the Federal Employees Health Benefits Program (FEHBP) spends on esophageal cancer care and to check whether FEHBP enrollees at high risk are getting recommended screening. The GAO must deliver the report to Congress within one year of the law taking effect. The law does not create new programs or funding; it requires a focused federal review to inform future policy or oversight about detection, screening, and spending for esophageal cancer among federal employees and retirees.
Introduced May 19, 2025 by Gerald E. Connolly · Last progress June 9, 2026